Exelixis Stock News

Exelixis issued two important releases regarding its lead molecule cabozantinib, showing positive results in prostate cancer and advanced pancreatic and extra-pancreatic neuroendocrine tumors. The com

We have narrowed our search to five mid-cap stocks that have provided double-digit returns in the past month. These are: FN, FRSH, HRB, EXEL, PSN.

Phase 3 CABINET study, using CABOMETYX to treat patients with advanced pancreatic cancer and advanced pancreatic neuroendocrine tumors, stopped early due to overwhelming efficacy. Results from the pha

Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.

The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon

Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks presents investors with the better value op

The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist ( VC ) companies increased investments from 2,200 in 2016 to 3,100 in

Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.

Exelixis, Inc. (NASDAQ:EXEL ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Mo

Exelixis (EXEL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.22 per share a year ago.

As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new